On August 4th, Gelonhui reported that tasly pharmaceutical group (600535.SH) has begun a phase III clinical trial of compound salvia Miltiorrhiza tablets (FDA clinical research application code: T89) for the prevention and treatment of acute mountain sickness in the United States FDA (the Food and Drug Administration) in 2021. See the company's "Announcement on the Progress of Applying for the Clinical Trial of T89 for Preventing and Treating Acute Mountain Sickness in the United States and Risk Warnings" (Announcement No.: LIN2021-040) for details. The company held a meeting with the FDA on the main progress of the clinical trial and recently received the meeting minutes.
Compound salvia Miltiorrhiza tablet is a modern and innovative traditional Chinese medicine developed exclusively by the company. It is used to treat angina pectoris caused by coronary heart disease and non-proliferative diabetic retinopathy of type I (mild) and type II (moderate) diabetes.
